enalkiren

Also Known As:

(N-(3-amino-3-methyl-1-oxobutyl)-4-methoxy-L-phenylalanyl)-N-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-L-histidinamide; A 64662; A-64662; Abbott 64662; L-Histidinamide, N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-, (1S-(1R*,2S*,3R*))-

Networked: 12 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - enalkiren: 12

Related Diseases

1.	Essential Hypertension 05/01/1995 - "We pursued this discrepancy in the current study of 18 healthy men and 9 men with essential hypertension, who each received one or more doses of enalkiren while on a fixed sodium diet. " 12/01/1990 - "The effect of the direct renin inhibitor enalkiren (Abbott Laboratories) was examined in 8 healthy patients with essential hypertension. " 12/01/1990 - "We conclude that enalkiren is effective in decreasing blood pressure and in inhibiting the renin system, without significantly altering urinary prostacyclin excretion, in patients with essential hypertension. " 06/01/1990 - "Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension." 03/01/1990 - "The effects of A-64662, a new specific renin inhibitor, on plasma renin activity (PRA) and blood pressure (BP) were studied for the first time in patients with essential hypertension. "
2.	Hypertension (High Blood Pressure) 01/01/1990 - "The results of clinical trials with enalkiren are encouraging, and suggest that renin inhibitors may be safe, useful therapeutic agents in the management of hypertension." 06/01/1990 - "The prolonged reduction in blood pressure with enalkiren without evidence of tachyphylaxis after 1 week of treatment suggests that renin inhibitors may emerge as useful therapeutic agents for the treatment of hypertension." 06/01/1990 - "To evaluate the participation of the renin-angiotensin system in sustaining hypertension, we administered the specific dipeptide renin inhibitor enalkiren (A-64662) to 18 patients with essential hypertension. "
3.	Heart Failure 05/01/1993 - "This study describes the relationship between the measured effects (the acute effects on systemic hemodynamics and cardiac function) and plasma drug levels using a combined pharmacokinetic-pharmacodynamic model after i.v. infusion dosing of enalkiren (A-64662) in patients with congestive heart failure. " 01/01/1991 - "Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure."
4.	Hypotension (Low Blood Pressure) 03/01/1989 - "This study indicates that continuous infusion of A-64662 results in a sustained hypotension in sodium-depleted monkeys. "
5.	Ganglion Cysts (Ganglion) 11/01/1999 - "The intravenous infusion of recombinant human renin (2.4 microg x kg(-1) x min(-1)) in the ganglion-blocked, nephrectomized rat produced a mean blood pressor response of 47+/-3 mm Hg (1 mm Hg = 133.3 Pa), which was reduced by captopril, enalkiren, and losartan in a dose-dependent manner following oral administration, with ED50 values of 0.3+/-0.1, 2.5+/-0.9, and 5.2+/-1.6 mg/kg, respectively. "

Related Drugs and Biologics

1.	Renin
2.	Epoprostenol (Prostacyclin)
3.	Sodium
4.	Renin Inhibitors
5.	Dipeptides
6.	Losartan (Cozaar)
7.	Captopril (Capoten)
8.	Angiotensin II
9.	Aldosterone

Related Therapies and Procedures

1.	Intravenous Injections
2.	Intravenous Infusions
3.	Oral Administration